Upcoming and on demand events.
The latest Diaceutics virtual event, “Precision medicine in oncology”, will allow you to join the forefront of cancer testing and treatment, with a series of 8 live webinars, culminating in a full day true-to-life virtual event. During these events, you’ll get exclusive access to clinical insights from top European lab experts.
CE-IVDR: where are we now in molecular testing?
12th December 2023, 15:00 CET.
The implementation of the new CE-In Vitro Diagnostics Regulation (IVDR) involves challenges faced by labs that are working within the diagnostic environment. The aim of this event is to get an overview of how IVDR implementation is progressing in different countries, and which are the most relevant challenges from a molecular pathology point of view. Five guest speakers from The Netherlands, France, Spain, Italy, and the UK with experience in the field will share their point of view and discuss the current situation and future perspectives.
Don't miss this opportunity to gain comprehensive insights into CE-IVDR, including the it's challenges. Join us for event 3 in the “Precision medicine in oncology’ series.
Sign up today
Immunotherapy insights: Biomarker testing and multi-disease treatment options
28th September 2023, 12:00pm CET
In the first event of this exciting series, key opinion leaders from the precision oncology field shared insights on the state of the art both in terms of biomarker testing and clinical utility of the use of immunotherapy as a multi-disease treatment option. Dr. Luiz Paz-Ares, Hospital Universitario 12 de Octubre, and Dr. Phillipe Taniere, University Hospitals Birmingham, explored across different oncological diseases, the importance of biomarkers such as PD-L1, MMR/MSI, and TMB for immunotherapy response and what are mandatory patient criteria for biomarker testing.
Liquid biopsy in oncohematology: Ready for clinic?
8th November 2023, 13:00 CET.
Event 2 in the series included an illuminating webinar featuring two distinguished experts in the field of oncohematology as they delve into the cutting-edge realm of liquid biopsies, their pivotal role in the detection of minimal residual disease (MRD) and investigate their role in the diagnostics of aggressive B cell lymphoma and multiple myeloma. Guest speakers Dr. Sven Borchmann from the University of Cologne, and Prof. Mattia D'Agostino from the University of Turin will guide participants through liquid biopsy as applied in B cell lymphoma, the profound implications of MRD, and techniques in the context of multiple myeloma and precision medicine. Attendees can participate in interactive sessions and engage in real-time Q&A sessions with the expert speakers, providing a chance to ask questions and gain a deeper insight and understanding of these increasingly relevant topics.